Assertio Therapeutics, Inc
DelistedCIK 1005201fmd_1BHJ8V9FDB7MQKMNT81WTYF55NManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Mar 31, 2020, 41 periods
| Line item | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 81 | 133 | 91 | 134 | 390 | 343 | 456 | 381 | 312 | 230 |
| Cost of revenue | 8 | 6 | 6 | 7 | 15 | 68 | 87 | 73 | – | – |
| Gross profit | 73 | 127 | 85 | 127 | 375 | 275 | 368 | 308 | – | – |
| Research and development | 20 | 15 | 15 | 8 | 7 | 18 | 33 | 14 | 8 | 10 |
| Selling, general and administrative | 49 | 82 | 98 | 105 | 121 | 199 | 204 | 196 | 119 | 109 |
| Operating income | 4 | 71 | (30) | 9 | 237 | (50) | 25 | (42) | 44 | (194) |
| Interest expense | 1 | 0 | 0 | 1 | 9 | 73 | 84 | 74 | 69 | 58 |
| Other non-operating income (expense) | 0 | 0 | 0 | (5) | (24) | (73) | (89) | (62) | (6) | (28) |
| Income before taxes | 4 | 71 | (30) | 5 | 213 | (123) | (65) | (104) | 38 | (222) |
| Income tax expense | (0) | 0 | (0) | (39) | 81 | (47) | 24 | (1) | 1 | (5) |
| Net income from continuing operations | 4 | 71 | (30) | 43 | 132 | (76) | (89) | (102) | 37 | (217) |
| Net income | 4 | 71 | (30) | 43 | 132 | (76) | (89) | (102) | 37 | (217) |